Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

May 03, 2007 08:00 ET

Stem Cell Therapeutics Corp. Retains MaisonBrison for Media and Investor Relations

CALGARY, ALBERTA--(CCNMatthews - May 3, 2007) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) has retained the services of MaisonBrison to assist in the Corporation's media and investor relations and corporate communications initiatives. Their mandate includes the execution of targeted communications strategies as well as a dedicated investor relations program to further position SCT within the financial markets.

SCT President and CEO, Dr. Alan Moore, stated that the company has entered a pivotal period in its growth. "We are developing a drug therapy, NTx™-265, to revive the growth of lost or damaged brain tissue and feel it is imperative that we keep the market fully informed of our progress. The engagement of MaisonBrison is in line with several key milestones established earlier this year as we dedicate our resources to enhance shareholder value."

"We are honoured that Stem Cell Therapeutics has retained MaisonBrison to raise the Corporation's profile in the financial community and with the public at large," indicated Rick Leckner, MaisonBrison President. "We are particularly pleased to help bring recognition to this emerging biotech company as it is poised to make inroads into the debilitating effects of central nervous systems diseases."

Under the terms of the agreement, which is subject to approval by the TSX Venture Exchange, the investor relations firm will receive monthly fees of $8,000. The fees will be paid out of the Corporation's general funds. No stock options have been granted to MaisonBrison.

About NTx™-265: NTx™-265 is a therapeutic regimen of two drugs being developed by SCT for the treatment of stroke. Human chorionic gonadotropin (hCG) is the first drug administered in the regimen, and aims to increase the number of neural stem cells (NSCs) located in the brain of a patient suffering from a recent stroke. Erythropoietin (EPO) is the second drug administered in the regimen, and aims to promote the differentiation of these newly formed NSCs into new neurons. New neurons thus formed are anticipated to provide benefit to the patient through the replacement of the brain cells that were lost or damaged by the stroke. Animal studies have shown a significant recovery in motor function in animals that have been given a stroke and subsequently been treated with the NTx™-265 therapy. Currently, SCT is enrolling patients in a phase IIa clinical trial in the United States in order to investigate the safety and efficacy of NTx™-265 in humans.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. (SCT) is a biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. SCT's currently enrolling phase IIa clinical program for NTx™-265 targets the treatment of stroke by repurposing approved and clinically well defined drugs. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases.

About MaisonBrison (MB): Founded in 1983, MaisonBrison meets the communications needs of a number of Canadian public and private companies. MaisonBrison offers a wide range of services. Specializing in investor relations, public relations and media relations, MB also offers graphic design and computer graphics services and organizes marketing roadshows. The firm acts as the communications department on clients' behalf or enables them to outsource certain functions of their choice.

MB's team consists of specialists in finance and communications. The firm also has strategic alliances in Toronto, Calgary and New York City.

For further information on Stem Cell Therapeutics Corp., visit

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information